Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Charles River Laboratories International Inc.

Creightons ( ($GB:CRL) ) has shared an announcement. Creightons plc has disclosed that Steve Denison, a person closely associated with non-executiv...

Creightons Discloses Share Purchase by Associate of Non-Executive Director

Cardinal Energy ( ($TSE:CJ) ) has shared an update. Cardinal Energy has unveiled a conservative C$75 million capital program for 2026 aimed at bala...

Cardinal Energy Sets Conservative $75 Million 2026 Budget with 15% Production Growth Target

In a report released yesterday, Chris Thompson MBA from CIBC maintained a Hold rating on Cardinal Energy, with a price target of C$7.75. The compan...

CIBC Reaffirms Their Hold Rating on Cardinal Energy (CJ)

RBC Capital analyst Rob Mann maintained a Buy rating on Cardinal Energy yesterday and set a price target of C$9.00. According to TipRanks, Mann is ...

RBC Capital Sticks to Its Buy Rating for Cardinal Energy (CJ)

Cardinal Energy ( ($TSE:CJ) ) has issued an update. Cardinal Energy Ltd. has confirmed a cash dividend of $0.06 per common share for January, payab...

Cardinal Energy Lifts Output at Reford SAGD, Maintains Dividend Amid Price Volatility

The latest announcement is out from Charles River Labs ( ($CRL) ). On January 8, 2026, Charles River Laboratories announced a leadership transition...

Charles River Labs Announces CEO Succession and Leadership Changes

Citi analyst Patrick B Donnelly maintained a Buy rating on Charles River Labs on January 2. The company’s shares closed last Friday at $202.42. Acc...

Current Quarter	$2.33	Next Quarter	$2.53
Current Year	$10.22	Next Year	$10.68
QoQ Growth	+8.6%	YoY Growth	+4.5%
3Y EPS CAGR	-70.5%	Target Price	$221.64
Consensus	Buy	Upside	+3.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRL	$213.22	+1.30%	403.00K
3
4
5

CRL

CRL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Charles River Laboratories International Inc. Data in Excel

Get Charles River Laboratories International Inc. Data in Excel